DeutschNewstral
Article
bizjournals.com on 2021-08-24 18:41
Main Line biopharma firm behind Covid-19 therapy raises $30M to advance product line
Related news
- Main Line biopharma firm raises $25 millionbizjournals.com
- Main Line cell therapy developer raises $50Mbizjournals.com
- Main Line biopharma firm expects $65M from stock sale; shares soarbizjournals.com
- Main Line gene therapy company is trading exchangesbizjournals.com
- Main Line's Aclipse Therapeutics lands $720K from Australia research firm to advance ALS therapybizjournals.com
- Pittsburgh bank buys another Main Line investment management firm for $30Mbizjournals.com
- Covid-19 therapy developer on the Main Line has another strong day on Wall Streetbizjournals.com
- Main Line pharma company plans key study of Fragile X syndrome therapybizjournals.com
- Main Line cell therapy startup adds Adaptimmune's CTO to its teambizjournals.com
- U.K. biopharma buys Homology Medicines' gene therapy manufacturing businessbizjournals.com
Product Hunt’s Starting LineTechCrunch
$30M Advance to WE Charity Still Outstanding?canadafreepress.com- Main Line biotech firm raises $40M in Series A round to advance new high blood pressure treatmentbizjournals.com
Arenel introduces new product linechronicle.co.zw
Agribank secures $30m line of creditherald.co.zw
Victory Energy adds product linejournalrecord.com- CAssociate Product Line Manager, Baseballchicagogolfreport.com
Medifast announces new product linethedailyrecord.com- C218 Market expands product linecarrollcountycomet.com
- IColdwater Seafood expands product lineislandadvantages.com